DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous
STADA sales companies once again successful in tenders for discount
agreements in the German generics market - very good results in the
second Barmer GEK tender round
04.06.2012 / 12:57
---------------------------------------------------------------------
Bad Vilbel, June 4, 2012 - The STADA sales companies STADApharm GmbH, ALIUD
PHARMA GmbH and cell pharm Gesellschaft für pharmazeutische und
diagnostische Präparate mbH were very successful in the second round of
tenders of Barmer GEK for discount agreements pursuant to Section 130 a SGB
V valid throughout Germany.
In the framework of this most recent Barmer GEK round with a total tender
volume of approximately Euro 408 million, the three STADA sales companies
were able to conclude contracts for a total of 13 active ingredients with
Barmer GEK, the second largest German public health insurance organization,
in which about 8.5 million of the patients covered by state insurance in
Germany are members.
Nine of the active ingredients awarded are thereby accounted for by
STADApharm, three active ingredients by ALIUD PHARMA and one active
ingredient by cell pharm. The contracts are legally effective, start on
August 1, 2012 and have a regular term of two years. Each respective STADA
sales company acts as the single contract partner (single source) for the
individual awards.
In light of all the discount agreements signed over recent months, among
others in the context of the recent 8th AOK tender round, the STADA
Executive Board continues to expect that the Group's market share by volume
in the German market will increase further. STADA's market share by volume
in the first quarter of 2012 amounted to approximately 13.4 percent and was
thus one percent above the corresponding period of the previous year of
approximately 12.4 percent.
Additional information:
STADA Arzneimittel AG / Corporate Communications / StadastraÃe 2-18 / D -
61118 Bad Vilbel /
Tel.: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-Mail:
communications@stada.de /
Or visit us in the Internet at www.stada.com.
End of Corporate News
---------------------------------------------------------------------
04.06.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime
Standard); Freiverkehr in Berlin, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
172727 04.06.2012
DGAP-News: STADA sales companies once again successful in tenders for discount agreements in the German generics market - very good results in the second Barmer GEK tender round
| Source: EQS Group AG